BAJAJ HEALTHCARE Share price

The Company was incorporated as Bajaj Healthcare Pvt. Ltd. on July 15 1993 under the Companies Act 1956 with the Registrar of Companies Mumbai bearing Registration Number - 072892. The status of the Company was changed to a public limited company and the name of the Company was changed to Bajaj Healthcare Ltd. by a special resolution passed on March 15 2005. A fresh certificate of incorporation consequent to the change of name was granted to the Company on March 31 2005 by the Registrar of Companies Mumbai. The Company?s Corporate Identity Number is U99999MH1993PLC072892. the Company Bajaj Healthcare Limited is a pharmaceutical company with manufacturing and marketing capabilities in Active Pharmaceutical Ingredients (APIs) Intermediates and Finished Dosage Formulations (FDFs) with focus on Vitamins Amino Acids Anti-Convulsants and Finished Dosage Forms (FDFs) catering to various therapeutic segments. the Company began its operations in the year 1993 with an API manufacturing unit in Tarapur near Mumbai. Over the years we have expanded the scale and scope of operations and currently we operate five (5) manufacturing units for manufacture of APIs Intermediates and Formulations. As part of this expansion in the year 2006 we acquired a 46000 sq. mtrs. plant in Savli Vadodara for setting up one of the biggest API and Intermediate manufacturing units. In the year 2008 with a view to enter into manufacturing of FDFs we acquired a 3000 sq. mtrs. Formulations plant at Manjusar Vadodara and we have converted it into a state-of-the-art WHO-GMP compliant facility. Keeping in momentum of the expansion in the year 2013 we set-up yet another API and Intermediate manufacturing unit at Panoli Ankleshwar. In the last fiscal i.e. in F. Y. 14-15 with the growing demand for APIs we decided to have a separate unit for Intermediate products so that the Savli and Panoli Units could concentrate on manufacture of APIs. Accordingly in November 2014 we acquired and set-up an Intermediate Unit in Tarapur MIDC near Mumbai. the Company?s present product portfolio consists of various APIs in the therapeutic categories of Neutraceutical (Amino Acids) Vitamins Anti-Convulsants Bactericidal & Bacteriostatic Diuretic & Vasodilator Mineral& Nutritional supplements Bronchodilater / Anti-asthmatic and Nootropics. the Formulations unit manufactures tablets capsules and sachets for the own brands as well as under Loan License (job work) for other pharmaceutical companies. Currently we manufacture formulations for GlaxoSmithKline Pharmaceuticals Limited (GSK) and USV Limited (USV) on a Loan License basis. The formulations manufactured for the own brands are manufactured and marketed under a separate division of Bajaj Medicare and we also have marketing tie-up with TTK Healthcare Limited. The FDFs manufactured by us cover various therapeutic segments like Antibiotics Anti-Arrhythmia Anti-Convulsants Anti-Diabetes Anti-Platelets NSAIDs Vitamins & its Derivatives Anti-Hypertensive Anti-Bacterial Anti-Malarial Cholinesterase Inhibitors etc. With the combined production of the API facilities and that of the Formulation unit the Company?s product portfolio consists of APIs and FDFs which shall be marketed in domestic and international markets as branded generics. Presently we are supplying the APIs and FDFs both domestically and exporting to various countries in regions like Europe USA Australia Africa South America etc. With the long standing operations and quality products we have built a strong relationship with the customers for both APIs and FDFs. Some of the major clients include nationally and internationally pharmaceutical companies like Glaxo Smithkline Consumer Healthcare Ltd. Ava Inc. Abbott Healthcare Pvt.Ltd Piramal Enterprises Ltd. Pfizer Ltd. Colgate Palmolive India Ltd. Lupin Ltd. and Intas Pharmaceuticals to name a few. We have an in-house R&D facility at the Tarapur Savli and Manjusar manufacturing units and a dedicated QC / QA & microbiology laboratory in all the Units to support technology transfer for new products and on-site process improvement. As on date of this Draft Prospectus we dedicated teams actively involved in R&D and QC / QA Lab activities. the R&D capabilities enable us to support the growth strategy by developing new products and processes which enhance the product range. The focus of the R&D has been to strive for continuous process improvements and achieving manufacturing cost efficiencies for existing as well as new APIs Intermediates and FDFs. The QA / QA and microbiology laboratories ensure the quality of raw material dispensed in the production process and also the finished goods delivered to the customers. This helps in improving the procurement process thus reducing wastages returns and other related costs.MAJOR EVENTS :1993-94-Incorporated under Companies Act 1956 as Bajaj Healthcare Private Limited by setting up plant at Tarapur1996-97-1st Export Sale 2004-2005-Changed the status of the Company from Private to Public i.e. to Bajaj Healthcare Limited.2005-2006-Purchase and Set-up a new facility at Salvi Vadodara -Purchase addition Plot N- 128 at Tarapur -Set up Corporate Office in Masjid Bunder (The same was acquired in FY 2003- 2004) 2006-2007-Issued 2000000 Non- Cumulative Preference Shares of 10/- each -Major Term loan of 863.00 lakhs was sanction and the total indebtedness reached to 2265 lakhs2007-2008-Purchase and Set-up a new facility at Manjusar Vadodara -Increase in Capacity of the major products like; 100% Vitamin C and its derivatives and 50% in Choline Bitartrate etc. 2009-2010-Launched own brands under Manjusar/ Medicare 2013-2014-Purchase and Set-up a new facility at Panoli Ankleshwar -1st GVK Agreement -1st USV Agreement 2014-2015-Purchase and Set-up a Second facility at Tarapur Maharashtra2015-2016-Acquisition of premises for new Corporate Office in Thane and set-up of the same.